Brooks to Participate in the UBS Virtual Global Healthcare Conference

CHELMSFORD, Mass., May 14, 2020 /PRNewswire/ — Brooks Automation, Inc. (Nasdaq: BRKS) announced today that company management will participate in the UBS Virtual Global Healthcare Conference on Wednesday, May 20, 2020 at 1:20 p.m. ET.  The 40-minute session will be webcast live via the Brooks investor relations website at www.brooks.investorroom.com/events. About Brooks AutomationBrooks (Nasdaq: BRKS) is... Read more

Zymo Research Obtains Emergency Use Authorization from FDA for Their Quick SARS-CoV-2 rRT-PCR Kit

Qualitative Test for the Detection of Nucleic Acid From SARS-CoV-2 IRVINE, Calif., (May 12, 2020) — Zymo Research announced today that the US Food and Drug Administration (FDA) has approved its Quick SARS-CoV-2 rRT-PCR Kit (R3011) for Emergency Use Authorization (EUA) for the detection of SARS-CoV-2, the virus that causes COVID-19. The kit is a qualitative test for the... Read more

New 6-year data for Roche’s OCREVUS (ocrelizumab) show earlier treatment initiation nearly halves risk of needing walking aid in relapsing multiple sclerosis

Post-hoc analysis from 6 years of Phase III open-label extension studies showed OCREVUS treatment reduced the risk of needing a walking aid (EDSS≥6) by 49% in relapsing multiple sclerosis (RMS) patients compared with patients who switched from interferon beta-1a two years later Separate analysis showed OCREVUS slowed thalamic volume loss in patients with RMS and... Read more

Roche’s risdiplam shows significant improvement in survival and motor milestones in infants with Type 1 spinal muscular atrophy (SMA)

FIREFISH Part 2 study met its primary endpoint by demonstrating a significant increase in motor milestones in infants aged 1-7 months after 12 months of treatment Large, pivotal global study confirms clinically meaningful efficacy seen in the dose-finding Part 1 of the trial Safety was consistent with the safety profile observed to date and no... Read more

Thermo Fisher Scientific adds Cefiderocol and Imipenem/Relebactam to manual and automated Antimicrobial Susceptibility Testing Platforms including ARIS HiQ

Thermo Fisher Scientific adds Cefiderocol and Imipenem/Relebactam to manual and automated Antimicrobial Susceptibility Testing Platforms including ARIS HiQ New FDA-cleared Microbroth Dilution Susceptibility Plates offer immediate testing options to microbiology laboratories providing the most up-to-date therapy for critically ill patients BASINGSTOKE, England, April 27, 2020 /PRNewswire/ — The antimicrobials Cefiderocol and imipenem/relebactam are now available on... Read more

Promega successfully completes first fully remote quality surveillance assessment amid COVID-19 restrictions

Biotech manufacturer recommended for continued certification to ISO 9001:2015 and ISO 13485:2016 Madison, WI USA. (April 17, 2020) Promega Corporation announced today it successfully completed its first ever fully remote quality surveillance assessment and is recommended for continued certification to ISO 9001:2015 and ISO 13485:2016. Due to COVID-19 restrictions, the British Standards Institution (BSI) completed its six-day... Read more

Brooks to Participate in the 19th Annual Needham Virtual Healthcare Conference

CHELMSFORD, Mass., April 8, 2020 /PRNewswire/ — Brooks Automation, Inc. (Nasdaq: BRKS) announced today that company management will participate in the 19th Annual Needham Virtual Healthcare Conference on Tuesday, April 14, 2020 at 10:40 a.m. ET.  The 40-minute session will be webcast live via the Brooks investor relations website at www.brooks.investorroom.com/events. About Brooks AutomationBrooks (Nasdaq: BRKS)... Read more

Roche provides regulatory update on risdiplam for the treatment of spinal muscular atrophy (SMA)

U.S. Food and Drug Administration (FDA) extends review time for risdiplam following agreed submission of additional data, including SUNFISH Part 2 Roche has submitted filing applications for risdiplam in seven countries with submission in China imminent Risdiplam is being investigated in infants, children and adults with Type 1, 2 or 3 SMA Basel, 07 April... Read more

Thermo Fisher Scientific Continues Investments to Accelerate Biopharma Commercialization

Thermo Fisher Scientific Continues Investments to Accelerate Biopharma Commercialization Capabilities and capacity now available to help customers of all sizes meet increasing demand for new biologics, cell and gene therapies, and drug products NEEDHAM, Mass., March 23, 2020 /PRNewswire/ — For biopharma companies faced with increasing demand for new biologics, cell and gene therapies, and drug... Read more

Statement on Jury Verdict in Delaware Trial Against Oxford Nanopore Technologies

MENLO PARK, Calif., March 18, 2020 (GLOBE NEWSWIRE) — Pacific Biosciences of California, Inc. (Nasdaq:PACB), a leading provider of high-quality sequencing of genomes, transcriptomes and epigenomes, announced that the jury verdict in the U.S. District Court for the District of Delaware was not overall favorable for Pacific Biosciences, but mixed in terms of its findings.... Read more